ID.1
Item
aggressive b-cell lymphoma, cd-20 positive, in first relapse or refractory to first-line chemotherapy
boolean
C0855090 (UMLS CUI [1,1])
C3888518 (UMLS CUI [1,2])
C0392920 (UMLS CUI [1,3])
ID.2
Item
diffuse large b-cell lymphoma, mantle cell lymphoma, follicular lymphoma (grade iii), transformed follicular lymphoma
boolean
C0079744 (UMLS CUI [1,1])
C0677725 (UMLS CUI [1,2])
C0024301 (UMLS CUI [1,3])
ID.3
Item
rituximab is allowed
boolean
C0393022 (UMLS CUI [1])
ID.4
Item
prior radiation is allowed
boolean
C1522449 (UMLS CUI [1])
ID.5
Item
18-70 years of age
boolean
C0001779 (UMLS CUI [1])
ID.6
Item
ecog performance status of 0-2
boolean
C3541269 (UMLS CUI [1])
ID.7
Item
hiv seronegative
boolean
C0019698 (UMLS CUI [1])
ID.8
Item
measurable disease on ct scan by international working group response criteria
boolean
C0040405 (UMLS CUI [1])
ID.9
Item
no cns involvement
boolean
C3714787 (UMLS CUI [1])
ID.10
Item
subject is considered to be a candidate for autologous stem cell transplant in the opinion of the treating physician
boolean
C2193200 (UMLS CUI [1])
ID.11
Item
female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control
boolean
C0009862 (UMLS CUI [1,1])
C0232970 (UMLS CUI [1,2])
ID.12
Item
male subject agrees to use an acceptable method of contraception for the duration of the study
boolean
C0009862 (UMLS CUI [1])
ID.13
Item
platelet count of <75 x 10(9)/l
boolean
C0032181 (UMLS CUI [1])
ID.14
Item
absolute neutrophil count of <1.0 x 10(9)/l
boolean
C0151683 (UMLS CUI [1])
ID.15
Item
calculated or measured creatinine clearance of <60 ml/minute within 14 days before enrollment
boolean
C0373595 (UMLS CUI [1])
ID.16
Item
myocardial infarction within 6 months prior to enrollment or has new york hospital association class iii or iv heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. prior to study entry, any ecg abnormality at screening has to be documented by the investigator as not medically relevant.
boolean
C0018799 (UMLS CUI [1])
ID.17
Item
subject has hypersensitivity to bortezomib, boron or mannitol.
boolean
C1176309 (UMLS CUI [1,1])
C0006030 (UMLS CUI [1,2])
C0024730 (UMLS CUI [1,3])
C0020517 (UMLS CUI [1,4])
ID.18
Item
female subject is pregnant or breast-feeding.
boolean
C0032961 (UMLS CUI [1,1])
C0006147 (UMLS CUI [1,2])
ID.19
Item
subject has been treated with more than one prior chemotherapy regimen.
boolean
C0392920 (UMLS CUI [1])
ID.20
Item
subject has received other investigational drugs with 14 days before enrollment.
boolean
C0013230 (UMLS CUI [1])
ID.21
Item
serious medical or psychiatric illness likely to interfere with participation in this clinical study.
boolean
C0004936 (UMLS CUI [1,1])
C0012634 (UMLS CUI [1,2])